Summary of Study ST000490

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000370. The data can be accessed directly via it's Project DOI: 10.21228/M87604 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis | Show all samples | Show named metabolites | Download named metabolite data
Download mwTab file (text) | Download mwTab file(JSON)

Study ID	ST000490
Study Title	Sleep apnea and cardiovascular samples nueromodulators panel
Study Summary	Sleep apnea and cardiovascular samples nueromodulators panel
Institute	Mayo Clinic
Laboratory	Mayo Clinic Metabolomics Resource Core
Last Name	Pak
First Name	Victoria
Address	unknown
Email	victoria.pak@yale.edu
Phone	203-737-5065
Submit Date	2016-10-14
Analysis Type Detail	LC-MS
Release Date	2018-10-10
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR000370
Project DOI:	doi: 10.21228/M87604
Project Title:	Mayo Metabolomics Pilot and Feasibility Award: Mechanisms of sleep apnea and cardiovascular disease
Project Type:	MS targeted analysis
Project Summary:	Targeted Metabolic and Biological Markers of Sleepiness Symptoms in Sleep apnea and cardiovascular disease
Institute:	Mayo Clinic
Laboratory:	Mayo Clinic Metabolomics Resource Core
Last Name:	Pak
First Name:	Victoria
Address:	unknown
Email:	victoria.pak@yale.edu
Phone:	203-737-5065

Subject:

Subject ID:	SU000511
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Species Group:	Human

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id	local_sample_id	Disease
SA025464	ms5685-12	cardiovascular disease
SA025465	ms5685-11	cardiovascular disease
SA025466	ms5685-14	cardiovascular disease
SA025467	ms5685-16	cardiovascular disease
SA025468	ms5685-1	cardiovascular disease
SA025469	ms5685-10	cardiovascular disease
SA025470	ms5685-15	cardiovascular disease
SA025471	ms5685-13	cardiovascular disease
SA025472	ms5685-3	cardiovascular disease
SA025473	ms5685-9	cardiovascular disease
SA025474	ms5685-2	cardiovascular disease
SA025475	ms5685-4	cardiovascular disease
SA025476	ms5685-5	cardiovascular disease
SA025477	ms5685-8	cardiovascular disease
SA025478	ms5685-7	cardiovascular disease
SA025479	ms5685-6	cardiovascular disease
SA025480	ms5685-31	sleep apnea
SA025481	ms5685-30	sleep apnea
SA025482	ms5685-29	sleep apnea
SA025483	ms5685-32	sleep apnea
SA025484	ms5685-36	sleep apnea
SA025485	ms5685-28	sleep apnea
SA025486	ms5685-35	sleep apnea
SA025487	ms5685-34	sleep apnea
SA025488	ms5685-33	sleep apnea
SA025489	ms5685-19	sleep apnea
SA025490	ms5685-21	sleep apnea
SA025491	ms5685-20	sleep apnea
SA025492	ms5685-18	sleep apnea
SA025493	ms5685-17	sleep apnea
SA025494	ms5685-22	sleep apnea
SA025495	ms5685-23	sleep apnea
SA025496	ms5685-26	sleep apnea
SA025497	ms5685-25	sleep apnea
SA025498	ms5685-24	sleep apnea
SA025499	ms5685-27	sleep apnea

Showing results 1 to 36 of 36

Showing results 1 to 36 of 36

Collection:

Collection ID:	CO000505
Collection Summary:	For the metabolic markers, 9 ml blood will be drawn into 3 EDTA tubes (3 ml each) and gently centrifuged at 4°C for 10 min; plasma aliquots were immediately frozen and stored at -80 °C; will be stored at -80ºC in the CTRC until all samples are collected and then sent to Mayo Clinic Metabolomics Core via LC-MS/MS for simultaneous detection and quantification of metabolites for analyses.
Sample Type:	Blood

Treatment:

Treatment ID:	TR000525
Treatment Summary:	Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study.

Treatment ID:

TR000525

Treatment Summary:

Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study.

Sample Preparation:

Sampleprep ID:	SP000518
Sampleprep Summary:	nueromodulators panel

Combined analysis:

Analysis ID	AN000756
Analysis type	MS
Chromatography type	Reversed phase
Chromatography system	Waters Acquity
Column	Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
MS Type	ESI
MS instrument type	Triple quadrupole
MS instrument name	Thermo Quantum Ultra
Ion Mode	POSITIVE
Units	micromolar

Chromatography:

Chromatography ID:	CH000542
Instrument Name:	Waters Acquity
Column Name:	Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
Chromatography Type:	Reversed phase

MS:

MS ID:	MS000668
Analysis ID:	AN000756
Instrument Name:	Thermo Quantum Ultra
Instrument Type:	Triple quadrupole
MS Type:	ESI
Ion Mode:	POSITIVE